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Summary
Although gene transfer of human apolipoprotein E (apoE), a 34-kDa circulating glycoprotein, to the liver of apoE-
deficient (apoE
-/-) mice using recombinant adenoviral vectors (rAd) is antiatherogenic, its full therapeutic potential
has yet to be realized. First generation vectors led to immune clearance of transduced hepatocytes, while an
improved vector with adenovirus regions E1, E3 and DNA polymerase deleted also had transient effects due to
cellular shutdown of the cytomegalovirus (CMV) promoter. Here, we have studied an alternative promoter from the
cellular elongation factor 1a (EF-1a) gene, injecting 6-8 week old apoE
-/- mice intravenously with 2x10
10 virus
particles (vp) of the [E1
-, E3
-, polymerase
-] rAd vector Ad-EF1·-apoE. Plasma apoE levels were low (18-55 ng/ml)
and failed to reduce plasma cholesterol or normalize the adverse lipoprotein profile. By contrast, the
hyperlipidaemic phenotype of apoE
-/- mice treated with Ad-CMV-apoE (2x10
10 vp) was transiently normalized.
Nevertheless, at termination (265 days) the aortic lesion areas in animals given Ad-EF1·-apoE were significantly
reduced by 15% (P<0.05) compared to untreated animals, a decrease approaching that in Ad-CMV-apoE-treated
mice (23%; P<0.02). Importantly, the attenuation of apoE transgene expression noted with the CMV promoter was
absent with the EF-1a promoter, which gave relatively sustained, albeit low, levels of plasma apoE throughout the
study period.Harris et al: Adenoviral apoE and atherosclerosis retardation
24
I. Introduction
Apolipoprotein E (apoE) is a 34-kDa glycoprotein
which plays a major role in plasma cholesterol
homeostasis and in protection against the development of
atherosclerosis. It is an important constituent of
atherogenic remnant lipoprotein particles, mediating their
hepatic clearance through interaction with the LDL-
receptor (LDLR) and LDLR-related protein (LRP)
(Mahley and Rall, 2000). Additionally, apoE is involved in
reverse cholesterol transport, where excess cholesterol is
removed from arterial and other peripheral tissues and
transported to the liver for excretion (Fielding and
Fielding et al, 1995; Mahley and Rall, 2000).
The apoE-deficient (apoE
-/-) mouse has severe
hypercholesterolaemia and spontaneously develops
atherosclerotic lesions (Piedrahita et al, 1992; Nakashima
et al, 1994). First generation recombinant adenovirus
(rAd) vectors were successful in liver-directed apoE gene
transfer, transiently normalizing plasma cholesterol levels
in apoE
-/- mice and protecting against atherosclerosis
(Kashyap et al, 1995; Stevenson et al, 1995). However,
such rAds led to an immune response against the
adenovirus-transduced hepatocytes, causing rapid loss of
transgene expression (Yang et al, 1996). Improvements in
rAd vector design, including removal of certain sequences
in the vector genome, reduced hepatotoxicity and allowed
longer apoE transgene expression (Tsukamoto et al, 1997,
1999; Harris et al, 2002a). This work included our own
study on intravenous (liver-directed) injections of a [E1
-,
E3
-, polymerase
-] rAd vector containing the
cytomegalovirus (CMV) promoter driving expression of
human apoE. We reported retardation of early aortic
lesions and acute regression of advanced atheroma in
apoE
-/- mice with normalization of the hyperlipidaemic
phenotype (Harris et al, 2002a). However, the apoE
transgene expression remained transient, as reflected in a
rebound of the plasma cholesterol concentration and the
re-accumulation of atherogenic remnant lipoprotein
particles to pretreatment levels. This effect was shown to
arise from CMV promoter shutdown, a recognized feature
of transgene expression when driven by virus-derived
promoters such as the CMV or Rouse sarcoma virus
(RSV) promoters, particularly in the liver (Kay et al, 1992;
Guo et al, 1996; Loser et al, 1998; Qin et al, 1997).
Therefore, in the current study we have constructed
an [E1
-, E3
-, polymerase
-] rAd vector, containing the
promoter for cellular elongation factor 1a (EF-1a), a
widely expressed eukaryotic protein involved in regulation
of multiple cellular processes, to drive expression of apoE.
ApoE
-/- mice (6-8 weeks old) were injected intravenously
with Ad-EF1a-apoE to assess its effect on
hyperlipidaemia and atherosclerotic lesion progression.
Although expression of apoE was low, the attenuation
noted with the CMV promoter appeared absent.
Importantly, at termination (265 days) treated mice
demonstrated significant retardation of atherosclerosis (15
%, P <0.05), compared to untreated endpoint control
animals, despite unchanged plasma cholesterol or
lipoprotein profile.
II. Materials and methods
A. Recombinant adenovirus construction
Construction of pShuttle-EF1a-pA has been described
(Ding et al, 2002). To construct the shuttle plasmid pShuttle-
EF1a-apoE-pA, human apoE3 cDNA was excised from pUC18-
apoE3 (Breslow et al, 1982) by digestion with HindIII and
BamH1, then ligated into HindIII-BamH1-digested pcDNA3. The
HindIII and XhoI subfragment of pcDNA3-apoE containing the
human apoE3 cDNA was subcloned into the HindIII and SalI
sites of pShuttle-EF1a-pA to yield pShuttle-EF1a-apoE-pA.
Construction of pShuttle-CMV-apoE-pA and the procedure for
generating the [E1
-, E3
-, polymerase
-] rAd vectors (Ad-CMV-
apoE and Ad-EF1a-apoE; Figure 1A) have been described
(Harris et al, 2002a).
B. Ad-EF1a-apoE infection of cultured
HepG2 and C2C12 cells
The human hepatic carcinoma and murine myoblast cell
lines, HepG2 and C2C12 respectively, were cultured and
transduced with rAd vectors as previously described (Harris et al,
2002a). Briefly, cells were seeded into 6-well plates and the
following day the near-confluent monolayers were infected with
the same dilutions of Ad-EF1a-apoE at the multiplicity of
infections (MOIs) indicated in Figure 1B. The next day culture
medium was changed to include 5% fetal calf serum (FCS) and,
after overnight incubation, the medium was harvested and
analysed by Western blotting for secreted apoE (Harris et al,
2002a).
C. Intravenous administration of rAd vectors
Female C57BL/6 apoE
-/- mice (Piedrahita et al, 1992) were
provided by GlaxoSmithKline (Stevenage, UK) and were
maintained on a normal chow diet. At age 6-8 weeks they were
intravenously injected via the tail-vein with either Ad-EF1a-
apoE (n = 6) or Ad-CMV-apoE (n = 7) at 2x10
10 virus particles
(vp) in 250 ml, where the virus stock was diluted appropriately in
diluent containing 10 mM Tris-HCl (pH 8.0), 2 mM MgCl2 and
0.9% (w/v) NaCl; untreated animals were used as controls (n =
7). Blood (~50 ml) was taken from the tail-vein following 4 h
fasts at 5, 14, 28, 56, 132 and 265 days post-injection, anti-
coagulated with sodium citrate and the plasma stored at -80°C.
The mice were killed at termination (265 days) to examine the
effect of apoE gene transfer upon aortic atherosclerotic lesion
progression. However, one Ad-CMV-apoE-treated animal died 7
days before this time point and so no analysis of the aorta was
carried out.
D. Quantification of plasma apoE and
cholesterol and analysis of lipoprotein distribution
Levels of human apoE in mouse plasma were monitored by
Western blotting and quantified by a two-antibody sandwich
ELISA as described earlier (Harris et al, 2002a). Total
cholesterol was measured in plasma diluted 1/10 in PBS (10 ml)
using a commercial enzymatic kit (Infinity
™ cholesterol reagent,
Sigma-Aldrich) and microtitre plates. Lipoprotein profiles were
evaluated by electrophoresis of 10 ml pooled plasma on pre-cast
alkaline buffered (pH 8.8) 0.8% agarose gels (YSI, Farnborough,
UK), followed by staining with Sudan black, as previously
described (Harris et al, 2002a).
E. Dissection and examination of the aortic
arch for atherosclerotic lesions
The animals were killed 265 days after the injections and aortae
were removed, pinned out en face onto cork beds and stained
with Oil-Red-O. Images of the aortae were captured with aGene Therapy and Molecular Biology Vol 9, page 25
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Nikon digital camera and analysis of aortic lesion area from the
aortic root of the heart down to the diaphragm was achieved
using image analysis software Sigma Scan Pro5 (Harris et al,
2002a).
F. Statistical analysis
Student’s unpaired t-test was used to compare plasma
cholesterol levels and aortic lesion areas in mice treated with Ad-
EF1a-apoE or Ad-CMV-apoE, against the untreated control
group.
III. Results
A. ApoE secretion by HepG2 and C2C12
cells transduced with Ad-EF1a-apoE
The rAd vector, Ad-EF1a-apoE containing the
cellular EF-1a promoter driving expression of human
apoE cDNA, was used to engineer human HepG2 cells
and mouse C2C12 myoblast cells to secrete apoE into the
culture supernatant. A higher transduction efficiency was
seen in HepG2 cells above endogenous levels of apoE
compared to C2C12 cultures, most evident when near-
equivalent virus particle MOIs were taken into account
(Figure 1B). The mock-infected and untreated HepG2
cells show basal endogenous apoE secretion.
Figure 1. Structural details of the recombinant adenovirus vectors used and their ability to transduce cells in vitro. (A) Schematic
representation of the [E1
-, E3
-, polymerase
-] adenovirus vectors expressing human apoE. The transgene cassettes that replace the deleted
E1-region, contained either the EF-1a promoter or the full CMV early enhancer/promoter driving expression of the human apoE3
cDNA, followed by a SV40 polyadenylation signal (pA). The solid triangles indicate the regions deleted in the recombinant adenovirus
(rAd) backbone. (B) Secretion of recombinant human apoE (34-kDa) from HepG2 and C2C12 myoblast cultures after infection with Ad-
EF1a-apoE.
.Harris et al: Adenoviral apoE and atherosclerosis retardation
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B. Secretion of human apoE into mouse
plasma following intravenous injection of Ad-
EF1a-apoE
Tail-vein bleeds were taken at 5, 14, 28, 56, 132 and
265 days after intravenous vector administration, with all
animals being killed at 265 days. Treatment with Ad-
CMV-apoE resulted in mean peak plasma apoE levels of
645±100 ng/ml 5 days after injection, compared to 50-80
mg/ml in normal mice (Hasty et al, 1999b), with
subsequent bleeds showing a substantial decline to 12±5
ng/ml at termination (Figure 2A). This was confirmed by
Western blotting which showed a marked reduction in the
34-kDa apoE transgene after 5 days (Figure 2A). In
contrast, intravenous injection of Ad-EF1a-apoE resulted
in very low peak levels of apoE at day 5 (<60 ng/ml),
while at later times they were too close to the ELISA
detection limit of 10 ng/ml to measure reliably (Figure
2B).
Figure 2. Plasma apoE levels in apoE
-/- mice after intravenous injection of either (A) Ad-CMV-apoE (n = 7) or (B) Ad-EF1a-apoE (n =
6). Plasma apoE (34-kDa) in individual animals was detected by Western blotting analysis and quantified by a two-antibody sandwich
ELISA that had a detection limit of 10 ng apoE/ml (Harris et al, 2002a). Exposure times for the Western blotting analysis were 30 min
(5, 14, 28, 56 and 132 days post-injection) and 75 min (265 days post-injection). Comparison can be made between the various panels in
figures 2A and 2B due to the inclusion on each gel of a plasma sample from transgenic mice containing human apoE2 (van Vlijmen et al,
1996), as a loading detection standard (data not shown). The levels of plasma apoE in normal mice are in the range 50-80 mg/ml (Hasty
et al, 1999b). *Plasma apoE is below the sensitivity limit of the ELISA for accurate quantification.Gene Therapy and Molecular Biology Vol 9, page 27
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However, Western blotting with an extended exposure
time revealed that apoE was still secreted at 265 days
(Figure 2B) and, despite the amounts being very low,
there was evidence to suggest that expression was
sustained since levels were similar at days 56 and 132 and
still detectable at 265 (Figure 2B). Upon Western blotting
analysis of plasmas from untreated animals, no circulating
apoE was evident (data not shown).
C. Effect of Ad-EF1a-apoE
administration on plasma total cholesterol
and lipoprotein distribution
Plasmas from individual animals were analysed for
total cholesterol and lipoprotein distribution before rAd
vector administration, and at 5, 14, 28, 56, 132 and 265
days after the injections, to assess whether human apoE
gene transfer could normalize the hypercholesterolaemia
of apoE
-/- mice. In Ad-CMV-apoE-treated mice, total
plasma cholesterol declined dramatically from 503±126
mg/dl to 153±62 mg/dl (P <0.002) 5 days after the
injections (Figure 3A). Subsequently, plasma cholesterol
returned to the pre-treatment level after 56 days (551±28
mg/dl) and, although increasing further (665±46 mg/dl) at
132 days (Figure 3A), was nearly identical to the levels in
untreated animals at day 265 (P>0.05).
Very-low-density lipoprotein (VLDL), intermediate-
density lipoprotein (IDL) and low-density lipoprotein
(LDL) particles represent the majority of plasma
lipoproteins in apoE
-/- mice, migrating as a broad preb-
band, with high-density lipoproteins (HDL) running as a
fast a migrating minor fraction (Figure 3B).
Figure 3. Effect of adenovirus vector administration on total plasma cholesterol and lipoprotein distribution in apoE
-/- mice. (A) Total
plasma cholesterol levels were determined for individual animals following tail-vein injections of either Ad-CMV-apoE (n = 7) or Ad-
EF1a-apoE (n = 6). The shaded area indicates the range of plasma cholesterol levels found in normal mice (Plump et al, 1992; Zhang et
al, 1992). Values are means ± S.E. and data from untreated animals are also shown. (B) Lipoprotein distribution in pooled plasmas from
apoE
-/- mice following intravenous injections of either Ad-CMV-apoE or Ad-EF1a-apoE. Plasma samples (10 Ìl) were separated by
0.8% native agarose gel electrophoresis, followed by staining with Sudan black to reveal lipoprotein mobilities and estimate relative
amounts. wt, plasma from a C57BL/10 mouse.Harris et al: Adenoviral apoE and atherosclerosis retardation
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In contrast, C57BL/10 mice have lower proportions of
VLDL/IDL/LDL, with increased levels of circulating
HDL. Following intravenous administration of Ad-CMV-
apoE, these preb-migrating lipoproteins were markedly
reduced at 5 days (Figure 3B), with a corresponding
increase in HDL, although thereafter VLDL/IDL/LDL
began to re-accumulate in the plasma, in fact, to higher
levels than those observed prior to the treatment (compare
lanes 132 and 0, left panel, Figure 3). In contrast to these
hypolipidaemic effects, “albeit short-term”, of Ad-CMV-
apoE, intravenous injection of Ad-EF1a-apoE produced
no significant changes in plasma cholesterol or lipoprotein
distribution in the apoE
-/- mice (Figure 3A and 3B).
D. Retardation of atherosclerotic lesion
progression following intravenous injection of
Ad-EF1a-apoE
To assess the effect of Ad-EF1a-apoE on
atherosclerotic lesion progression, animals were killed 265
days post-treatment and their aortae removed. The
percentage of luminal area from the aortic arch to the
diaphragm which stained with Oil-Red-O was then
measured. Mice treated with Ad-EF1a-apoE had aortic
lesion areas of 27.7±1.9% (n = 6), a 15% retardation of
lesion progression (P <0.05) compared to untreated
Figure 4. Retardation of atherosclerosis progression in the aortae of 6-8 week old apoE
-/- mice following adenovirus vector
administration. Animals were killed 265 days after intravenous administration of either Ad-CMV-apoE or Ad-EF1a-apoE; their aortae
were removed, dissected en face onto cork beds and stained with Oil-Red O. (A) Representative aortae from each of the animal groups.
(B) Mean percentage aortic lesion areas of Ad-CMV-apoE- (n = 6) and Ad-EF1a-apoE-treated (n = 6) mice and the untreated control
group (n = 7). Values shown are mean ± S.E. *, comparison of Ad-CMV-apoE- and Ad-EF1a-apoE-treated mice against the untreated
control group by Student’s 1-tailed unpaired t-test.Gene Therapy and Molecular Biology Vol 9, page 29
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controls (32.8±2%, n = 7) (Figure 4A and 4B). This
reduction was similar to those animals treated with Ad-
CMV-apoE, which had a mean lesion area of 25.3±2.3%
(n = 6) and a 23% retardation of lesion progression (P
<0.02) (Figure 4A and 4B).
IV. Discussion
Here we report a significant retardation of aortic
atherosclerotic lesion progression in young apoE
-/- mice
intravenously injected with the [E1
-, E3
-, polymerase
-]
rAd vector, Ad-EF1a-apoE, despite low expression of the
human apoE transgene and no reduction in plasma total
cholesterol or atherogenic remnant lipoproteins. This is
consistent with intramuscular injection of apoE
-/- mice
with plasmid or recombinant adeno-associated virus
(rAAV) vectors expressing apoE, as these treatments also
result in low plasma apoE but protect against
atherosclerosis without correcting the
hypercholesterolaemia (Athanasopoulos et al, 2000; Harris
et al, 2002b). Similarly, transgenic mice in which apoE
expression is restricted to adrenal glands or macrophages
have low plasma apoE (1-2% of wild-type levels), but are
atheroprotected whilst remaining hyperlipidaemic
(Thorngate et al, 2000, Hasty et al, 1999a). Intriguingly,
studies in which apoE
+/+ bone marrow was mixed with
apoE
-/- marrow in increasing amounts and then
transplanted into apoE
-/- recipient mice suggests that a
threshold concentration of ~0.4 mg apoE/ml plasma is
required for cholesterol homeostasis (Hasty et al, 1999b).
Our own data following intravenous injections of Ad-
CMV-apoE supports this conclusion; the initial
normalization of plasma cholesterol and subsequent
rebound, mirrors the level of apoE on days 5 (0.65±0.1
mg/ml), 14 (0.4±0.09 mg/ml) and 28 (0.17±0.05 mg/ml)
(Figure 3A).
Recombinant apoE is known to localize to the arterial
intima following rAd-mediated liver transduction
(Tsukamoto et al, 1999). This may explain why treatment
with Ad-EF1a-apoE inhibits atherosclerotic lesion
progression in the presence of high levels of atherogenic
lipoproteins, since atheroprotection is also seen when
apoE expression in transgenic apoE
-/- mice is restricted to
the artery wall or to macrophages (Bellosta et al, 1995;
Shimano et al, 1995). One proposed mechanism is that
apoE promotes cholesterol efflux from the arterial wall
and its transport to the liver for excretion (Bellosta et al,
1995; Shimano et al, 1995). In support, there is evidence
that macrophage-derived apoE can restore the capacity of
apoE-deficient plasma to efflux cholesterol from cultured
fibroblasts (Zhu et al 1998) and that apoE facilitates
interaction of apoA1 in HDL particles with scavenger
receptor-B1 (SR-B1), which selectively extracts
cholesteryl esters from HDL into liver (Arai et al 1999,
Owen and Mulcahy, 2002). Paradoxically, however,
cholesterol efflux via the ATP-binding cassette transporter
A1 (ABCA1) is impaired by low level apoE expression
(Thorngate et al, 2003) and increasing importance is now
given to alternative, non-lipid transport mechanisms which
can contribute to the antiatherogenic activity of apoE
(Thorngate et al, 2003). These include apoE inhibition of
platelet aggregation (Riddell et al, 1997) and smooth
muscle cell migration and proliferation (Ishigami et al,
1998), as well as antioxidant (Mabile et al, 2003) and anti-
inflammatory activities (Stannard et al, 2001). Recently,
Raffai et al, (2005) demonstrated for the first time that
apoE promotes regression of atherosclerosis independently
of lowering plasma cholesterol. They utilized
hypomorphic apoE mice that express an apoE4-like
variant of mouse apoE at plasma levels that are ~2% to 5%
of normal and carry the inducible Mx1-Cre apoE
transgene, which allows for induction of physiological
levels of apoE. After 18 weeks on a hypercholesterolaemic
diet to induce a high atherosclerotic burden, animals were
placed on a normal chow diet for 16 weeks, with half the
animals induced to express physiological levels of apoE.
Although cholesterol levels between the non-induced and
induced animal groups was insignificant, the induced
animals demonstrated an enhanced regression of aortic
atheroma (Raffai et al, 2005). In this study, the levels of
apoE produced from the EF-1a promoter corresponded to
a maximum of 0.11% of normal levels throughout the
study period.
The EF-1a promoter appears attractive to drive
hepatic expression of transgenes. It was active in a variety
of cultured cell types, providing greater and more stable
expression than the promoters of the SV40 early gene or
the long terminal repeat of RSV (Kim et al, 1990, 1993).
Whilst in vivo, it gave ubiquitous and sustained expression
of the cellular marker chloramphenicol acetyltransferase
(CAT), during generation of transgenic mice from
embryogenesis to adulthood (Hanaoka et al, 1991). These
findings are consistent with the emerging concept that
non-viral promoters invoke a diminished immune response
to expressed transgenes compared to viral promoters
(Pastore et al, 1999; Hartigan-O’Connor et al, 2001; Bojak
et al, 2002) and have encouraged the use of the EF-1a
promoter in gene transfer studies. Thus, a first generation
rAd vector, delivered to immunodeficient mice by
intravenous injection to drive expression of human a1-
antitrypsin (hAAT), produced sustained physiological
levels of serum hAAT protein throughout the 3 month
study, with 80-90% of vector genomes targeted to the liver
(Guo et al, 1996). In addition, portal vein injection of adult
C57BL/6 mice with a rAAV vector expressing human
factor IX (hFIX) from the EF-1a promoter produced
therapeutic plasma levels of hFIX (200-320 ng/ml) for at
least 6 months, whereas with the CMV promoter no
plasma hFIX was detected at this time due to promoter
shutdown (Nakai et al, 1998). Hence, in this study, the
utilization of a polymerase-deleted rAd vector may have
contributed to the sustained transgene expression, as the
removal of the polymerase from the rAd vector genome
virtually eliminates adenoviral late gene expression, which
significantly reduces hepatotoxicity as well as removing
the primary trigger for the immune clearance of
adenovirus-transduced cells (Amalfitano et al, 1998; Hu et
al, 1999; Everett et al, 2003).
Disappointingly, however, we found only low levels
of circulating apoE in vivo following transduction with
2x10
10 vp of Ad-EF1a-apoE, even though previously
reported data would predict that >95% of hepatocytesHarris et al: Adenoviral apoE and atherosclerosis retardation
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would be infected, since adult mice have ~10
8 liver cells
giving a theoretical MOI of ~200 (Li et al, 1993).
Furthermore, real-time PCR data from our laboratory has
shown 2 copies of second generation Ad vector genomes
per hepatocyte (Harris et al, 2002a; JDH, unpublished
observation). This differed from the efficient secretion of
apoE by HepG2 cells, markedly above endogenous levels,
perhaps because actively cycling cell cultures have higher
levels of EF-1a compared to adult hepatocytes in vivo,
which proliferate slowly (Leffert et al, 1982).
Additionally, interference from transcriptional elements in
the adenovirus genome may cause low apoE expression by
interfering with transcriptional activity of heterologous
transgene promoters. These viral sequences include the
inverted terminal repeats (ITRs), the E1A enhancer and
the E2, E4 and protein IX (pIX) promoters (Steinwaerder
and Lieber, 2000). Typically, transgene cassettes replace
the E1-deleted region of the Ad genome. This leaves
5’ITR/E1A and pIX orientated 5’ and 3’, respectively and
these sequences contain inhibitory elements that can
attenuate the activity and tissue specificity of transgene
expression. For example, insertion of the 5’ITR and pIX
regions into a plasmid vector containing a muscle-specific
promoter caused decreased expression of a reporter gene
and loss of muscle-specific expression (Shi et al, 1997).
But why should a 1
st generation rAd containing the
EF-1a promoter produce therapeutic amounts of the
plasma protein hAAT (Guo et al, 1996), when only low
level expression occurs with Ad-EF1a-apoE? One
possibility is that first generation vectors have a degree of
background replication and viral gene expression that
augments transgene expression of a protein such as hAAT.
An alternative possibility is that though the E1 region is
deleted from both rAd vectors, cellular transcription
factors functionally substitute for E1A to transactivate the
E2 and E4 promoters, which then interfere with transgene
expression from the heterologous promoter (EF1a)
(Steinwaerder and Lieber, 2000). Presumably such
interference is nominal in first generation E1-deleted rAd,
whereas our 2
nd generation rAd vector with the DNA
polymerase deleted is more vulnerable. In future work, it
may be possible to circumvent this problem by use of
insulating DNA elements to shield the transcriptional
activity of the apoE transgene cassette from adenoviral
sequence interference. Thus, when insulator elements
derived from the chicken b-globin locus (HS-4) flanked
the transgene cassette in a first generation rAd vector, the
performance of a metal-inducible promoter was markedly
improved (Steinwaerder and Lieber, 2000). Alternatively,
promising results are reported using newly-developed
liver-specific promoters (Gehrke et al, 2003; Ziegler et al,
2004; Nakai et al, 2005) and, although they have yet to be
tested in rAd vectors, these offer further hope for sustained
high-level liver expression of therapeutic transgenes.
In summary, liver-directed administration of Ad-
EF1a-apoE to apoE
-/- mice produced only low levels of
plasma apoE, but  retarded the progression of early fatty
streak lesions to advanced atherosclerotic plaques, despite
failing to normalize the hyperlipidaemic phenotype. In
addition, we suggest that interference from transcriptional
elements in the rAd vector genome may have caused the
low levels of EF-1a promoter-driven apoE transgene
expression and propose the use of DNA insulator elements
to counteract this problem in future studies.
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